Results 201 to 210 of about 8,214 (218)

Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease: an open randomised trial

Lancet, The, 2008
Geert D'Haens, Martine De Vos, Séverine Vermeire   +2 more
exaly  

Crohn's disease management after intestinal resection: a randomised trial

Lancet, The, 2015
Peter De Cruz, Michael A Kamm, Alexandra Gorelik   +2 more
exaly  

Enfermedad inflamatoria del tubo digestivo. Enfermedad de Crohn

Medicine - Programa de Formaci?n M?dica Continuada Acreditado, 2008
F. Calvo Hernn, J. Hinojosa del Val
openaire   +1 more source

Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study

Lancet, The, 2017
Geert D'Haens, Julian Panes, Arthur Kaser   +2 more
exaly  

Clinical remission in patients with moderate-to-severe Crohn's disease treated with filgotinib (the FITZROY study): results from a phase 2, double-blind, randomised, placebo-controlled trial

Lancet, The, 2017
Séverine Vermeire, Xavier Hébuterne, Xavier Roblin   +2 more
exaly  

Early combined immunosuppression for the management of Crohn's disease (REACT): a cluster randomised controlled trial

Lancet, The, 2015
Reena Khanna, Guangyong, Remo Panaccione
exaly  

Microbial network disturbances in relapsing refractory Crohn’s disease

Nature Medicine, 2019
Bahtiyar Yilmaz, Pascal Juillerat, Nicolas Fournier   +2 more
exaly  

Defective acute inflammation in Crohn's disease: a clinical investigation

Lancet, The, 2006
Anthony Segal
exaly  

Perianal fistulizing Crohn's disease: pathogenesis, diagnosis and therapy

Nature Reviews Gastroenterology and Hepatology, 2017
Julian Panes, Jordi Rimola
exaly  

Crohn's disease

Lancet, The, 2017
Joana Torres, Saurabh Mehandru, Laurent Peyrin-Biroulet   +2 more
exaly